论文部分内容阅读
二甲双胍(Metformin)是一种抗糖尿病的双胍类衍生物,用于治疗非胰岛素依赖型糖尿病,此外它还能影响脂代谢,因此在动物和人体实验中能预防动脉粥样硬化,并能诱导脂蛋白组成的改变。作者研究了24例无糖尿病而患有ⅡB型高脂血症的患者,观察二甲双胍对血清脂蛋白、血脂及血小板功能等的影响。随机给患者服用两种剂量(每日1.0 g和2.0 g)和安慰剂各9周。结果表明,二甲双胍可引起血清胆固醇和LDL-胆固醇的剂量依赖性下降,平均血清总胆固醇浓度按服用安慰剂、1.0 g和2.0 g二甲双胍的顺序分别为8.54
Metformin is an anti-diabetic biguanide derivative for the treatment of non-insulin-dependent diabetes mellitus, in addition to its effect on lipid metabolism, thus preventing atherosclerosis in animals and humans and inducing lipid Changes in protein composition. The authors studied 24 non-diabetic patients with type IIB hyperlipidemia and observed the effects of metformin on serum lipoproteins, lipids and platelet function. Patients were randomized to two doses (1.0 g and 2.0 g daily) and placebo for 9 weeks. The results showed that metformin caused a dose-dependent decrease in serum cholesterol and LDL-cholesterol, with mean serum total cholesterol concentrations of placebo, with 1.0 g and 2.0 g of metformin in the order of 8.54